KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Equity Ratio (2016 - 2025)

Biogen has reported Equity Ratio over the past 17 years, most recently at 0.62 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.62 for Q4 2025, up 4.06% from a year ago — trailing twelve months through Dec 2025 was 0.62 (up 4.06% YoY), and the annual figure for FY2025 was 0.62, up 4.06%.
  • Equity Ratio for Q4 2025 was 0.62 at Biogen, up from 0.0 in the prior quarter.
  • Over the last five years, Equity Ratio for BIIB hit a ceiling of 0.62 in Q2 2025 and a floor of 0.0 in Q3 2025.
  • Median Equity Ratio over the past 5 years was 0.55 (2022), compared with a mean of 0.51.
  • Biggest five-year swings in Equity Ratio: rose 21.53% in 2023 and later tumbled 99.69% in 2025.
  • Biogen's Equity Ratio stood at 0.46 in 2021, then increased by 18.79% to 0.55 in 2022, then grew by 1.11% to 0.55 in 2023, then grew by 8.1% to 0.6 in 2024, then increased by 4.06% to 0.62 in 2025.
  • The last three reported values for Equity Ratio were 0.62 (Q4 2025), 0.0 (Q3 2025), and 0.62 (Q2 2025) per Business Quant data.